IDEV Technologies Strengthens Commercial Leadership

Informations

• Publié par: idev-technologies-inc-allen-caron
• Nombre de lectures: 11
• Langue: English

Extrait

IDEV Technologies Strengthens Commercial

Leadership

PR Newswire

WEBSTER, Texas, June 6, 2012

WEBSTER, Texas

,

June 6, 2012

/PRNewswire/ -- IDEV Technologies, Inc. (IDEV),

an emerging innovator in peripheral vascular devices, announced the hiring of

Trent Reutiman as Vice President, Global Commercial Operations. He joins the

company after successful sales and marketing positions at ROX Medical and

several other start-ups. His early career was in sales and sales management at

Guidant and Cordis.

In addition to Reutiman, IDEV has further supplemented the global team with

additional hires in key areas including the commercial organization, product

development, and operations as the company continues to develop its business

through organic growth, new product launches, and geographic expansion.

"The addition of Trent to our senior management team is a reflection of our

commitment to further expand our capabilities, and to execute our long term

strategy," commented Christopher Owens, President and CEO of IDEV. "All the

new resources bring global experience that further enhances our existing

organization as we work to develop and complement our unique technology

platform."

Reutiman, in this newly created role, will lead the global sales and marketing

teams as the company continues to expand distribution and sales of its flagship

product, the SUPERA® stent.

"I'm excited to join IDEV at this time," commented Reutiman. "With recent

product launches in multiple countries in the

Asia Pacific

region, continued

market penetration in

Europe

, and intense preparations for the anticipated FDA

approval of the SUPERA stent in the U.S., we are setting strategies that are vital

to successful commercial execution."

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next

generation medical devices for use in interventional radiology, vascular surgery

and cardiology. IDEV's worldwide headquarters is located in

Webster, Texas

and its European headquarters is located in Beuningen,

The Netherlands

.

The SUPERA stent is currently indicated in

the United States

for the palliative

treatment of biliary strictures produced by malignant neoplasms and in multiple

other countries for the treatment of biliary strictures produced by malignant

neoplasms and for peripheral vascular use following failed percutaneous

transluminal angioplasty (PTA).

For more information please visit www.idevmd.com.

Contact:

Donna Lucchesi

Vice President Global Marketing

IDEV Technologies, Incorporated

[phone]